Finance

Lists
Why is PHAT down 6,95%?
Dive Deeper
PHAT:NASDAQ
Phathom Pharmaceuticals Inc
5,28 USD
-6,95%
(-0,39) 1D
5-ноя., 13:48:31 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PHAT...
Open
5,70 USD
High
5,70 USD
Low
5,24 USD
Mkt. cap
429,63 млн
Avg. vol.
1,65 млн
Volume
528,18 миң
52-wk high
18,31 USD
52-wk low
5,02 USD
EPS
-1,03 USD
Beta
0,69
Shares outstanding
81,29 млн
No. of employees
371
Open
5,70 USD
High
5,70 USD
Low
5,24 USD
Mkt. cap
429,63 млн
Avg. vol.
1,65 млн
Volume
528,18 миң
52-wk high
18,31 USD
52-wk low
5,02 USD
EPS
-1,03 USD
Beta
0,69
Shares outstanding
81,29 млн
No. of employees
371
News stories
From web sources and news partners
About Phathom Pharmaceuticals Inc
CEO-
Employees371
Founded2018
HeadquartersФлорхем Парк, Нью Джерси, Америка Кошмо Штаттары
SectorHealth Care
IndustryPharmaceutical industry
Websitephathompharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to PHAT in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for PHAT in the last 3 months.
Highest
Current 5,28 USD
26,00 USD (+391,96%)
Average
16,90 USD (+219,77%)
Lowest
7,50 USD (+41,91%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Hold
Maintained
7,50 USD
+41,9%
11/02/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
22,00 USD
+316,3%
10/29/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
26,00 USD
+392%
10/30/2026
Jenna Davidner
Barclays
Buy
Maintained
14,00 USD
+164,9%
10/30/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
-
-
10/23/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
15,00 USD
+183,8%
10/21/2026
Martin Auster
Raymond James
Buy
Maintained
21,00 USD
+297,4%
07/31/2026
Joseph Stringer
Needham
Buy
Maintained
22,00 USD
+316,3%
07/30/2026
Paul Choi
Goldman Sachs
Hold
Maintained
-
-
04/30/2026
Last report
2026-ж., 29-окт.
Fiscal period
Q3 2026
0,04 USD / 0,03 USD
+39,86%beat
Revenue / Est. (USD)
84,72 млн / 84,82 млн
-0,12%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
57,58 млн
58,30 млн
74,27 млн
84,72 млн
Cost of goods sold
7,65 млн
12,00 млн
15,10 млн
18,37 млн
Cost of revenue
7,65 млн
12,00 млн
15,10 млн
18,37 млн
Research and development expenses
7,49 млн
7,77 млн
7,81 млн
8,74 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
48,37 млн
54,01 млн
55,33 млн
57,70 млн
Operating expense
55,86 млн
61,78 млн
63,14 млн
66,44 млн
Total operating expenses
63,51 млн
73,78 млн
78,24 млн
84,81 млн
Operating income
-5,93 млн
-15,48 млн
-3,96 млн
-85,00 миң
Other non operating income
-5,00 миң
-831,00 миң
-24,00 миң
-25,00 миң
EBT including unusual items
-21,15 млн
-30,37 млн
-17,58 млн
-13,90 млн
EBT excluding unusual items
-21,15 млн
-30,37 млн
-17,58 млн
-13,90 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-21,15 млн
-30,37 млн
-17,58 млн
-13,90 млн
Net profit margin
-36,73%
-52,09%
-23,67%
-16,40%
Earnings per share
-0,08
-0,18
-
0,04
Interest and investment income
1,20 млн
1,74 млн
1,51 млн
1,60 млн
Interest expense
-16,42 млн
-15,80 млн
-15,10 млн
-15,39 млн
Net interest expenses
-15,22 млн
-14,06 млн
-13,59 млн
-13,79 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-5,80 млн
-15,37 млн
-3,85 млн
35,00 миң
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору